MSB Trading 2021 - paradigm shift, page-7852

From the conference call that came with the annual report:

Jason Kolbert -- Dawson James -- Analyst

One quick question. It sounds like a lot of the bottleneck has to do with manufacturing CMC and/or if I want to be specific and pinpoint potency assay. And it seems like once you clear that road block that several clinical pathways get resolved. Are you feeling that same thinking that I'm -- am I on the right path?

Fred Grossman -- Chief Medical Officer

Absolutely. We just had an excellent meeting with the FDA, very collegial and a very positive meeting that has delineated for us exactly where we're going. We have very precise potency assays that are being developed that we think support the mechanism and the action of these cells in both acute graft versus host disease and COVID ARDS. And we will be providing the FDA in a meeting over the next quarter with more details around this potency development, and we expect to be updating the market shortly after that.


******

They have data from the covid trial that will help them with this.

By the way, people are blaming FDA for delay in getting to the OTAT meeting, but it is possible Mesoblast is still completing the analysis...